Literature DB >> 17668276

Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening.

Birgit Schlegel1, Christian Laggner, Rene Meier, Thierry Langer, David Schnell, Roland Seifert, Holger Stark, Hans-Dieter Höltje, Wolfgang Sippl.   

Abstract

The human histamine H(3) receptor (hH(3)R) is a G-protein coupled receptor (GPCR), which modulates the release of various neurotransmitters in the central and peripheral nervous system and therefore is a potential target in the therapy of numerous diseases. Although ligands addressing this receptor are already known, the discovery of alternative lead structures represents an important goal in drug design. The goal of this work was to study the hH(3)R and its antagonists by means of molecular modelling tools. For this purpose, a strategy was pursued in which a homology model of the hH(3)R based on the crystal structure of bovine rhodopsin was generated and refined by molecular dynamics simulations in a dipalmitoylphosphatidylcholine (DPPC)/water membrane mimic before the resulting binding pocket was used for high-throughput docking using the program GOLD. Alternatively, a pharmacophore-based procedure was carried out where the alleged bioactive conformations of three different potent hH(3)R antagonists were used as templates for the generation of pharmacophore models. A pharmacophore-based screening was then carried out using the program Catalyst. Based upon a database of 418 validated hH(3)R antagonists both strategies could be validated in respect of their performance. Seven hits obtained during this screening procedure were commercially purchased, and experimentally tested in a [(3)H]N(alpha)-methylhistamine binding assay. The compounds tested showed affinities at hH(3)R with K ( i ) values ranging from 0.079 to 6.3 muM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17668276     DOI: 10.1007/s10822-007-9127-x

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  47 in total

1.  Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third transmembrane domain.

Authors:  X Ligneau; S Morisset; J Tardivel-Lacombe; F Gbahou; C R Ganellin; H Stark; W Schunack; J C Schwartz; J M Arrang
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Completion and refinement of 3-D homology models with restricted molecular dynamics: application to targets 47, 58, and 111 in the CASP modeling competition and posterior analysis.

Authors:  J A Flohil; G Vriend; H J C Berendsen
Journal:  Proteins       Date:  2002-09-01

3.  G protein-coupled receptors: in silico drug discovery in 3D.

Authors:  Oren M Becker; Yael Marantz; Sharon Shacham; Boaz Inbal; Alexander Heifetz; Ori Kalid; Shay Bar-Haim; Dora Warshaviak; Merav Fichman; Silvia Noiman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

Review 4.  Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists.

Authors:  Holger Stark; Markus Kathmann; Eberhard Schlicker; Walter Schunack; Birgit Schlegel; Wolfgang Sippl
Journal:  Mini Rev Med Chem       Date:  2004-11       Impact factor: 3.862

5.  Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4.

Authors:  Nicolas Triballeau; Francine Acher; Isabelle Brabet; Jean-Philippe Pin; Hugues-Olivier Bertrand
Journal:  J Med Chem       Date:  2005-04-07       Impact factor: 7.446

6.  Molecular modeling and pharmacological analysis of species-related histamine H(3) receptor heterogeneity.

Authors:  B B Yao; C W Hutchins; T L Carr; S Cassar; J N Masters; Y L Bennani; T A Esbenshade; A A Hancock
Journal:  Neuropharmacology       Date:  2003-05       Impact factor: 5.250

7.  Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.

Authors:  Ramin Faghih; Wesley Dwight; Anil Vasudevan; Jurgen Dinges; Scott E Conner; Timothy A Esbenshade; Youssef L Bennani; Arthur A Hancock
Journal:  Bioorg Med Chem Lett       Date:  2002-11-04       Impact factor: 2.823

8.  Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists.

Authors:  G Meier; J Apelt; U Reichert; S Grassmann; X Ligneau; S Elz; F Leurquin; C R Ganellin; J C Schwartz; W Schunack; H Stark
Journal:  Eur J Pharm Sci       Date:  2001-06       Impact factor: 4.384

9.  Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).

Authors:  Robbie L McLeod; Charlie A Rizzo; Robert E West; Robert Aslanian; Kevin McCormick; Matthew Bryant; Yunsheng Hsieh; Walter Korfmacher; Garfield G Mingo; LoriAnn Varty; Shirley M Williams; Neng-Yang Shih; Robert W Egan; John A Hey
Journal:  J Pharmacol Exp Ther       Date:  2003-03-20       Impact factor: 4.030

10.  Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor.

Authors:  Niu Shin; Elizabeth Coates; Nicholas J Murgolo; Kelley L Morse; Marvin Bayne; Catherine D Strader; Frederick J Monsma
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

View more
  12 in total

1.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

2.  Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the beta2-adrenergic receptor and the human adenosine A2A receptor.

Authors:  Farag F Sherbiny; Anke C Schiedel; Astrid Maass; Christa E Müller
Journal:  J Comput Aided Mol Des       Date:  2009-11       Impact factor: 3.686

Review 3.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

4.  A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism.

Authors:  Susanne Neumann; Gunnar Kleinau; Stefano Costanzi; Susanna Moore; Jian-kang Jiang; Bruce M Raaka; Craig J Thomas; Gerd Krause; Marvin C Gershengorn
Journal:  Endocrinology       Date:  2008-07-31       Impact factor: 4.736

5.  Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists.

Authors:  Fouad H Darras; Steffen Pockes; Guozheng Huang; Sarah Wehle; Andrea Strasser; Hans-Joachim Wittmann; Martin Nimczick; Christoph A Sotriffer; Michael Decker
Journal:  ACS Chem Neurosci       Date:  2014-01-14       Impact factor: 4.418

6.  Physical binding pocket induction for affinity prediction.

Authors:  James J Langham; Ann E Cleves; Russell Spitzer; Daniel Kirshner; Ajay N Jain
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

7.  Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.

Authors:  Guo Li; Kendra M Haney; Glen E Kellogg; Yan Zhang
Journal:  J Chem Inf Model       Date:  2009-01       Impact factor: 4.956

8.  New vistas in GPCR 3D structure prediction.

Authors:  Anwar Rayan
Journal:  J Mol Model       Date:  2009-06-24       Impact factor: 1.810

9.  Drug design for ever, from hype to hope.

Authors:  G Seddon; V Lounnas; R McGuire; T van den Bergh; R P Bywater; L Oliveira; G Vriend
Journal:  J Comput Aided Mol Des       Date:  2012-01-18       Impact factor: 3.686

Review 10.  Docking and chemoinformatic screens for new ligands and targets.

Authors:  Peter Kolb; Rafaela S Ferreira; John J Irwin; Brian K Shoichet
Journal:  Curr Opin Biotechnol       Date:  2009-09-03       Impact factor: 9.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.